There is a perfect storm brewing in the healthcare industry. Over the past few years, there has been an unprecedented rise in the trade of illicit healthcare products in the secondary market.
Practice points in Israel patent prosecution: selection patents and treatment of earlier-filed patent applications
Israel patent practice is distinct from US and European practice in a number of respects. Moshe Tritel describes a number of such areas with important practical ramifications for applicants seeking to maximise their patent protection in Israel.
A recent study revealed that biotechnology companies or universities discovered 42 percent of all innovative drugs approved by the US Food and Drug Administration (FDA) between 1998 and 2007.
The traditional business model for a new drug relies on a substantial period of market exclusivity to recoup extensive research and development costs.
Natural products have been used to relieve a variety of diseases and conditions for millennia.
US patent reform looks like it may finally be coming. John Pegram and Mark Ellinger explain the proposed changes.
As biotechnology patents continue to grow in importance, uncertainty remains on both sides of the Atlantic as to exactly what is patentable. Simon O’Brien and David Gass take a look.
The Canadian Federal Court of Appeal recently considered whether ‘invalid selection’ can be an independent ground for invalidating selection patents. Katie Wang looks at the implications.
Recent European decisions have provided much to think about for practitioners concerned with DNA sequences. Caroline Pallard and Bart Swinkels investigate.
Practitioners can take heart from recent developments in the Brazilian courts, say Otto Licks and Anderson Nascimento.